ArticlePloS one2012
MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 67 citations in OpenAlex.
- The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women.Journal of cancer research and clinical oncology · 2023Article
- MicroRNA expression profiling of endocrine sensitive and resistant breast cancer cell lines.Biochemistry and biophysics reports · 2022Article
- Review
- 5,7,2,5-tetrahydroxy-8,6-dimethoxyflavone up-regulates miR-145 expression and inhibits proliferation of gastric cancer cells.Archives of medical science : AMS · 2022Article
- The antihyperlipidemic drug potassium piperonate impairs the migration and tumorigenesis of breast cancer cellsFrontiers in oncology · 2022Article
- Potential miRNAs for miRNA-Based Therapeutics in Breast Cancer.Non-coding RNA · 2020Review
- Effect of miR‑145 on gastric cancer cells.Molecular medicine reports · 2019Article
- Long non-coding RNA CASC9 knockdown inhibits the progression of nasopharyngeal carcinoma by regulating miR-145.International journal of clinical and experimental pathology · 2019Article
- Tocopherols inhibit estrogen-induced cancer stemness and OCT4 signaling in breast cancer.Carcinogenesis · 2018Article
- miR-372 promotes breast cancer cell proliferation by directly targeting LATS2.Experimental and therapeutic medicine · 2018Article
- Detection and analysis of circulating large intergenic non-coding RNA regulator of reprogramming in plasma for breast cancer.Thoracic cancer · 2018Article
- MicroRNA-1225-5p behaves as a tumor suppressor in human glioblastoma via targeting of IRS1.OncoTargets and therapy · 2018Article
- miR-143 and miR-145 inhibit gastric cancer cell migration and metastasis by suppressing MYO6.Cell death & disease · 2017Article
- Long non-coding RNAs as novel biomarkers for breast cancer invasion and metastasis.Oncology letters · 2017Article
- Downregulation of microRNA-145 promotes epithelial-mesenchymal transition via regulating Snail in osteosarcoma.Cancer gene therapy · 2017Article
- Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.Oncotarget · 2016Article
- MicroRNA-145 Inhibits Cell Migration and Invasion and Regulates Epithelial-Mesenchymal Transition (EMT) by Targeting Connective Tissue Growth Factor (CTGF) in Esophageal Squamous Cell Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- MiR-424-5p participates in esophageal squamous cell carcinoma invasion and metastasis via SMAD7 pathway mediated EMT.Diagnostic pathology · 2016Article
- A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas.Laboratory investigation; a journal of technical methods and pathology · 2016Article
- Tackling Cancer Stem Cells via Inhibition of EMT Transcription Factors.Stem cells international · 2016Review
Corrections and comments
- Retraction · 2013-05-20Concerns/Issues about Data · Error in Image · Investigation by Company/Institution · Removed ·
- Retracted
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MiR-145 could regulate tumor growth, apoptosis, migration, and invasion. In our present study, we investigated its role in epithelial-mesenchymal transition (EMT). Expression of miR-145 was decreased in breast tumor tissues at T3&4 stages in comparison with those at T1&2. Over-expression of miR-145 mimics enhanced protein levels of E-cadherin and dampened those of α-SMA and Fibronectin, indicative of its inhibitory role in EMT occurrence. Mechanistic studies showed that miR-145 mimics inhibited Oct4 expression and miR-145 inhibitor enhanced it. Over-expression of Oct4 reversed miR-145-regulated expression of EMT markers, suggesting that Oct4 mediated the inhibitory effects of miR-145. MiR-145 could inhibite the expression of Snail, ZEB1, and ZEB2, while over-expression of Oct4 rescued the effects. Furthermore, Oct-4 induced over-expression of transcription factor Snail, ZEB1 and ZEB2 was mediated by β-catenin. Expression of Slug and Twist were not altered by miR-145/Oct4. Taken together, our results have revealed a novel role of miR-145 on EMT. It inhibits EMT by blocking the expression of Oct4, and downstream transcriptional factors, Snail, ZEB1 and ZEB2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.